Compare Stocks

Date Range: 

 PfizerEli Lilly andNovartisAbbVieNovo Nordisk A/S
SymbolNYSE:PFENYSE:LLYNYSE:NVSNYSE:ABBVNYSE:NVO
Price Information
Current Price$38.81$218.55$93.01$113.12$82.28
52 Week RangeHoldBuyHoldBuyHold
MarketRank™
Overall Score1.92.12.02.61.3
Analysis Score2.12.53.21.40.0
Community Score2.92.82.32.92.1
Dividend Score2.51.72.55.02.5
Ownership Score0.81.70.01.70.0
Earnings & Valuation Score1.31.91.91.91.9
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyHold
Consensus Price Target$40.43$214.00$108.50$120.33N/A
% Upside from Price Target4.17% upside-2.08% downside16.65% upside6.38% upsideN/A
Trade Information
Market Cap$217.25 billion$209.59 billion$212.87 billion$199.80 billion$193.75 billion
Beta0.730.240.540.830.42
Average Volume30,332,6073,964,1671,959,7087,081,415985,816
Sales & Book Value
Annual Revenue$41.91 billion$24.54 billion$48.66 billion$45.80 billion$19.45 billion
Price / Sales5.188.544.374.369.96
Cashflow$3.01 per share$8.73 per share$8.46 per share$13.47 per share$3.04 per share
Price / Cash12.9125.0411.008.4027.10
Book Value$11.42 per share$6.09 per share$24.76 per share$7.42 per share$4.12 per share
Price / Book3.4035.893.7615.2519.97
Profitability
Net Income$9.62 billion$6.19 billion$8.07 billion$4.62 billion$6.46 billion
EPS$2.22$7.93$5.75$10.56$2.76
Trailing P/E Ratio19.8032.6726.7339.9728.57
Forward P/E Ratio11.9825.8013.828.0824.20
P/E Growth1.431.952.271.733.06
Net Margins22.09%23.91%16.31%10.28%33.77%
Return on Equity (ROE)24.55%132.28%24.15%136.75%71.90%
Return on Assets (ROA)9.61%16.36%10.27%12.95%30.84%
Dividend
Annual Payout$1.56$3.40$2.08$5.20$1.33
Dividend Yield4.02%1.56%2.24%4.60%1.62%
Three-Year Dividend Growth-10.94%42.31%13.60%84.37%13.65%
Payout Ratio70.27%42.88%36.17%49.24%48.19%
Years of Consecutive Dividend Growth1 Years1 Years1 Years49 Years1 Years
Debt
Debt-to-Equity Ratio0.51%2.28%0.51%5.40%0.05%
Current Ratio1.48%1.42%0.74%0.83%0.85%
Quick Ratio1.16%1.10%0.50%0.73%0.59%
Ownership Information
Institutional Ownership Percentage64.22%81.63%10.11%66.07%5.72%
Insider Ownership Percentage0.05%0.13%0.01%0.09%0.07%
Miscellaneous
Employees78,50035,000103,91447,00045,323
Shares Outstanding5.60 billion959.03 million2.29 billion1.77 billion2.35 billion
Next Earnings Date7/28/2021 (Confirmed)7/29/2021 (Estimated)7/20/2021 (Estimated)7/30/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Heres Why Altimmune Stock Is Surging TodayHere's Why Altimmune Stock Is Surging Today
finance.yahoo.com - June 16 at 3:35 PM
Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific SessionsNovo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions
prnewswire.com - June 16 at 9:29 AM
Novo Nordisk A/S (NYSE:NVO) Reaches New 12-Month High at $82.55Novo Nordisk A/S (NYSE:NVO) Reaches New 12-Month High at $82.55
americanbankingnews.com - June 8 at 10:38 AM
Novo Nordisk A/S (NYSE:NVO) Sees Unusually-High Trading VolumeNovo Nordisk A/S (NYSE:NVO) Sees Unusually-High Trading Volume
americanbankingnews.com - June 7 at 11:56 AM
Novo’s Wegovy Approved After Superior Weight-Loss Impact ShownNovo’s Wegovy Approved After Superior Weight-Loss Impact Shown
msn.com - June 7 at 12:07 AM
Novo Nordisks semaglutide set to tackle obesity with hotly-anticipated FDA green lightNovo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
fiercepharma.com - June 5 at 7:56 PM
U.S. FDA approves Novo Nordisks semaglutide as obesity treatmentU.S. FDA approves Novo Nordisk's semaglutide as obesity treatment
news.yahoo.com - June 5 at 7:56 PM
Novo Nordisk’s weight loss injection OK’d by FDANovo Nordisk’s weight loss injection OK’d by FDA
nny360.com - June 5 at 7:56 PM
Novo Nordisk’s Weight Loss Injection Receives FDA ApprovalNovo Nordisk’s Weight Loss Injection Receives FDA Approval
bloombergquint.com - June 4 at 5:58 PM
Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the USWegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
finance.yahoo.com - June 4 at 5:58 PM
UPDATE 2-U.S. FDA approves Novo Nordisks semaglutide as obesity treatmentUPDATE 2-U.S. FDA approves Novo Nordisk's semaglutide as obesity treatment
finance.yahoo.com - June 4 at 5:58 PM
FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%
finance.yahoo.com - June 4 at 5:58 PM
Novo Nordisk (NVO) Inks Deal to Develop Heart Failure TreatmentNovo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
finance.yahoo.com - June 1 at 2:15 PM
Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failureHeartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure
pipelinereview.com - June 1 at 4:14 AM
Novo Nordisk A/S : Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approvalNovo Nordisk A/S : Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
markets.businessinsider.com - May 29 at 10:10 AM
Senseonics vs. Novo Nordisk: Which Diabetes Stock is a Better Buy?Senseonics vs. Novo Nordisk: Which Diabetes Stock is a Better Buy?
investing.com - May 28 at 6:10 PM
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approvalNovo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
finance.yahoo.com - May 28 at 1:09 PM
Is Novo Nordisk A/S (NVO) A Smart Long-Term Buy?Is Novo Nordisk A/S (NVO) A Smart Long-Term Buy?
finance.yahoo.com - May 28 at 1:09 PM
3 European Stocks to Buy for International Exposure (NVO)3 European Stocks to Buy for International Exposure (NVO)
marketbeat.com - May 25 at 8:05 PM
Novo Nordisk Recalls Levemir, Tresiba, Fiasp, Novolog, Xultophy Product Samples Novo Nordisk Recalls Levemir, Tresiba, Fiasp, Novolog, Xultophy Product Samples
rttnews.com - May 11 at 6:16 AM
Novo Nordisk A/S (NYSE:NVO) share price rebounds 18.68% from the lows – but can it keep going?Novo Nordisk A/S (NYSE:NVO) share price rebounds 18.68% from the lows – but can it keep going?
marketingsentinel.com - May 8 at 2:01 PM
BRIEF-Novo Nordisk A/S Purchases B Shares Worth DKK 2,586 Million From Novo Holdings A/S Under The 2021 Share Repurchase ProgrammeBRIEF-Novo Nordisk A/S Purchases B Shares Worth DKK 2,586 Million From Novo Holdings A/S Under The 2021 Share Repurchase Programme
news.trust.org - May 7 at 7:11 PM
Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021
finance.yahoo.com - May 7 at 7:11 PM
PFE vs. NVO: Which Stock Should Value Investors Buy Now?PFE vs. NVO: Which Stock Should Value Investors Buy Now?
finance.yahoo.com - May 7 at 2:11 PM
Novo Nordisk A/S Stock Appears To Be Modestly OvervaluedNovo Nordisk A/S Stock Appears To Be Modestly Overvalued
gurufocus.com - May 7 at 1:24 AM
Novo Nordisk (spons ADRs) earnings: heres what to expectNovo Nordisk (spons ADRs) earnings: here's what to expect
markets.businessinsider.com - May 5 at 10:02 PM
DateCompanyBrokerageAction
6/17/2021PfizerRoyal Bank of CanadaBoost Price Target
6/15/2021PfizerBerenberg BankReiterated Rating
5/24/2021PfizerJPMorgan Chase & Co.Set Price Target
5/24/2021PfizerThe Goldman Sachs GroupSet Price Target
5/12/2021PfizerMizuhoReiterated Rating
5/10/2021PfizerMorgan StanleyBoost Price Target
5/5/2021PfizerSVB LeerinkBoost Price Target
5/5/2021PfizerBarclaysBoost Price Target
2/3/2021PfizerDZ BankReiterated Rating
6/8/2021Eli Lilly andTruist SecuritiesReiterated Rating
6/8/2021Eli Lilly andTruist FinancialReiterated Rating
2/12/2021Eli Lilly andCowenBoost Price Target
1/22/2021Eli Lilly andBank of AmericaBoost Price Target
12/10/2020Eli Lilly andWolfe ResearchUpgrade
11/10/2020Eli Lilly andSanford C. BernsteinInitiated Coverage
4/28/2021NovartisOddo BhfUpgrade
4/19/2021NovartisUBS GroupReiterated Rating
3/23/2021NovartisSociete GeneraleReiterated Rating
3/16/2021NovartisArgusReiterated Rating
1/15/2021NovartisDeutsche Bank AktiengesellschaftInitiated Coverage
6/15/2020NovartisCitigroupUpgrade
5/3/2021AbbVieBMO Capital MarketsBoost Price Target
4/30/2021AbbViePiper SandlerBoost Price Target
1/20/2021Novo Nordisk A/SCredit Suisse GroupDowngrade
1/3/2020Novo Nordisk A/SGuggenheimDowngrade
11/22/2019Novo Nordisk A/SPareto SecuritiesDowngrade
(Data available from 6/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.